logo-loader

Maxcyte deal with Allogene Therapeutics 'a clear endorsement' of its technology

Published: 10:21 26 Mar 2020 GMT

Proactive Research analyst Emma Ulker says MaxCyte’s (LON:MXCT) deal with clinical-stage industry leader Allogene Therapeutics (NASDAQ:ALLO) is a clear endorsement of the features of its Flow Electroporation technology.

Described by Allogene as the ‘industry standard’, MXCT’s Flow Electroporation has been chosen to improve yield and efficiency of its lead clinical programmes.  

Click here to read Emma Ulker's update on MaxCyte Inc "Allogene deal is validation for new CAR-T wave"

HANetf founder and co-CEO discusses shift to active management in ETF market

HANetf founder and co-CEO Hector McNeil tells Proactive's Stephen Gunnion about shifting trends in the exchange-traded fund (ETF) market in the United States, indicating a big move towards active management within ETFs. Despite the European market lagging behind the US by three to five years,...

15 hours, 2 minutes ago